Analysts See $-0.77 EPS for Editas Medicine, Inc. (EDIT); Lyon William Homes (class A) (WLH) Sellers Increased By 32% Their Shorts

April 19, 2018 - By Louis Casey

William Lyon Homes (NYSE:WLH) Logo

Lyon William Homes (class A) (NYSE:WLH) had an increase of 32% in short interest. WLH’s SI was 1.52M shares in April as released by FINRA. Its up 32% from 1.15 million shares previously. With 396,000 avg volume, 4 days are for Lyon William Homes (class A) (NYSE:WLH)’s short sellers to cover WLH’s short positions. The SI to Lyon William Homes (class A)’s float is 6.41%. The stock decreased 3.87% or $1.09 during the last trading session, reaching $27.07. About 223,173 shares traded. William Lyon Homes (NYSE:WLH) has risen 31.70% since April 19, 2017 and is uptrending. It has outperformed by 20.15% the S&P500.

Analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to report $-0.77 EPS on May, 21.They anticipate $0.08 EPS change or 9.41% from last quarter’s $-0.85 EPS. After having $-0.84 EPS previously, Editas Medicine, Inc.’s analysts see -8.33% EPS growth. The stock decreased 1.53% or $0.54 during the last trading session, reaching $34.81. About 729,873 shares traded. Editas Medicine, Inc. (NASDAQ:EDIT) has risen 60.37% since April 19, 2017 and is uptrending. It has outperformed by 48.82% the S&P500.

Editas Medicine, Inc. operates as a genome editing company. The company has market cap of $1.61 billion. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It currently has negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Among 5 analysts covering William Lyon Homes (NYSE:WLH), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. William Lyon Homes had 15 analyst reports since August 29, 2015 according to SRatingsIntel. UBS maintained William Lyon Homes (NYSE:WLH) rating on Wednesday, January 17. UBS has “Hold” rating and $33.0 target. The rating was maintained by Wedbush on Tuesday, February 21 with “Neutral”. The stock has “Hold” rating by Citigroup on Thursday, January 4. The stock has “Hold” rating by Wedbush on Friday, December 29. The company was upgraded on Thursday, September 17 by Zacks. The firm has “Hold” rating by Zacks given on Friday, September 4. On Wednesday, November 1 the stock rating was maintained by Wedbush with “Hold”. The rating was upgraded by Zacks on Saturday, August 29 to “Sell”. UBS maintained the shares of WLH in report on Wednesday, November 1 with “Neutral” rating. The firm has “Mkt Perform” rating by JMP Securities given on Thursday, January 12.

William Lyon Homes, together with its subsidiaries, designs, constructs, markets, and sells single-family detached and attached homes. The company has market cap of $1.06 billion. It operates in six divisions: California, Arizona, Nevada, Colorado, Washington, and Oregon. It has a 21.83 P/E ratio. The firm sells its homes primarily to entry-level, and first-time and second-time move-up homebuyers under the Village Homes and Polygon Northwest Homes brands through in-house commissioned sales personnel and outside brokers.

Editas Medicine, Inc. (NASDAQ:EDIT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts